Clinical trial
Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.
NCT00239109 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00239109 |
|---|---|
| Title | Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia. |
| Official title | Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia: A Six Months, Double Blind Randomized, Parallel Group Study. |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug, Procedure |
| Interventions | Ziprasidone, Olanzapine, Scales, measures of the body (Weight...), Serum analysis |
| Enrollment | 112 |
| Start date | Apr 1, 2003 |
| Completion | Feb 1, 2007 |
| First posted | Oct 14, 2005 |
| Last update posted | Feb 21, 2021 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: